Industrializing Design, Development, and Manufacturing of Therapeutic Proteins - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industrializing Design, Development, and Manufacturing of Therapeutic Proteins
The authors discuss various approaches and related issues, including production of difficult-to express proteins using cell-free expression systems, scalability of protein expression, and site-specific chemical modifications.


Pharmaceutical Technology
Volume 35, pp. s8-s11

References

1. K.J. Hamblett et al., Clin. Cancer Res. 10 (20), 7063–7070 (2004).

2. J.R. Junutula et al., Clin. Cancer Res. 16 (19), 4769–4778 (2010).

3. J.S. Ma, Chim. Oggi 21 (6), 65–68 (2003).

4. A.R. Goerke and J.R. Swartz, Biotechnol. Bioeng. 102 (2), 400–416 (2009).

5. I.S. Carrico, B.L. Carlson, and C.R. Bertozzi, Nat. Chem. Biol. 3 (6), 321–322 (2007).

6. A.J. de Graaf et al., Bioconjugate Chem. 20 (7), 1281–1295 (2009).

7. R. Mamluk et al., MAbs 2 (2), 199–208 (2010).

8. H. Mao et al., Nat. Biotechnol. 28 (11), 1195–2002 (2010).

9. J. Swartz, J. Ind. Microbiol.and Biotechnol. 33 (7), 476–485 (2006).

10. E.A Burks et al., Proc. Natl. Acad. Sci. 94 (2), 412–417 (1997).

11. L. Jermutus, L.A. Ryabova, and A. Pluckthun, Curr. Opin. Biotechnol. 9 (5), 534–548 (1998).

12. M.C. Jewett et al., Mol. Syst. Biol. 4, 220–end page (2008).

13. A.R. Goerke and J.R. Swartz, Biotechnol. Bioeng. 99 (2), 351–367 (2008).

14. J.F. Zawada et al., Biotechnol. Bioeng. in press (2011).

15. M. He, New Biotechnol. 25 (2–3), 126–132 (2008).

16. T. Tsuboi et al., Infect. Immun. 76 (4), 1702–1708 (2008).

17. J. Swartz Nat. Biotechnol. 27, 731–732 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here